Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bendamustine
Drug ID BADD_D00230
Description Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Indications and Usage Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Marketing Status Prescription
ATC Code L01AA09
DrugBank ID DB06769
KEGG ID D07501
MeSH ID D000069461
PubChem ID 65628
TTD Drug ID D01CYA
NDC Product Code 68554-0050
Synonyms Bendamustine Hydrochloride | Hydrochloride, Bendamustine | Bendamustine | Bendamustin | Cytostasan | IMET 3393 | Ribomustin | Treanda | Zimet 3393
Chemical Information
Molecular Formula C16H21Cl2N3O2
CAS Registry Number 16506-27-7
SMILES CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood pressure systolic increased13.14.03.0060.000799%Not Available
Blood uric acid increased13.02.04.0010.000533%Not Available
Body temperature increased13.15.01.0010.000799%Not Available
Bone pain15.02.01.001--
Bowen's disease23.08.02.004; 16.03.02.0040.000533%Not Available
Burning sensation17.02.06.001; 08.01.09.0290.000799%Not Available
C-reactive protein increased13.09.01.0070.000533%Not Available
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002--Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000139%Not Available
CD4 lymphocytes decreased13.01.06.0160.005328%
Cellulitis23.09.01.001; 11.02.01.0010.001066%Not Available
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.009--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.0010.004529%
Chronic lymphocytic leukaemia16.01.06.001; 01.10.06.0010.000347%Not Available
Chronic obstructive pulmonary disease22.03.01.0070.000208%Not Available
Colitis07.08.01.0010.000533%
Confusional state19.13.01.001; 17.02.03.0050.001865%
Constipation07.02.02.001--
Cough22.02.03.001--
Creatinine renal clearance increased13.13.01.0150.000533%Not Available
Crystalluria20.02.01.0030.000533%Not Available
Cytomegalovirus infection11.05.01.0020.001332%
Death08.04.01.001--
Dehydration14.05.05.0010.001598%
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.0030.000533%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 10 Pages